CDKN2A and neoplasm: Moreover, CDKN2A, a CRG,[10] participates in various cellular pathways, including inhibiting tumor cell apoptosis and enhancing tumor cell proliferation.[25] In addition, high expression of CDKN2A can affect the prognosis of patients by regulating tumor-associated macrophages.[26] In this study, the CRGs model was an independent prognostic factor for HCC with high prognostic accuracy.